Summary
Changes in peripheral blood immunological effector cells after systemic administration of recombinant interleukin 2 (rIL2) were studied in 14 patients with HBe antigen-positive chronic hepatitis. The patients were intravenously injected with rIL2 for 4 weeks, and the experiments were performed using mononuclear cells isolated from the peripheral blood during and after rIL2 administration. No significant changes in OKT4-positive cell population, OKT8-positive cell population, OKT4/OKT8 ratio and Leu7-positive cell population were detected during and after intravenous injection of rIL2. However, the natural killer (NK) cell and lymphokine-activated killer (LAK) cell activities significantly increased in the fourth week of rIL2 administration, while the K cell activity in the antibody-dependent cell-mediated cytotoxicity reaction, antibody response, lectininduced lymphocyte transformation and IL1 production of LPS-stimulated monocytes were not affected. These results suggest that IL2 increases the NK cell and LAK cell activitiesin vivo.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Farrar JJ, Benjamin WR, Hilfiker ML, et al: The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody-forming B cell responses. Immunol Rev 1982; 63:129–166
Andrew ME, Churilla AM, Malek TR, et al: Activation of virus specific CTL clones: Antigen-dependent regulation of interleukin 2 receptor expression. J Immunol 1985; 134:920–925
Rosenstein M, Yron I, Kaufmann Y, et al: Lymphokineactivated killer cells: Analysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Cancer Res 1984; 44:1946–1953
Domzig W, Stadler BM, Herberman RB: Interleukin 2 dependence of human natural killer (NK) cell activity. J Immunol 1983; 130:1970–1973
Lanier LL, Benike CJ, Phillips JH, et al: Recombinant interleukin 2 enhanced natural killer cell-medicated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens. J Immunol 1985; 134:794–801
Rosenberg SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with metastatic cancer. N Engl J Med 1985; 313:1485–1492
Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233:1318–1321
Rouse BT, Miller LS, Turtinen L, et al: Augmentation of immunity to herpes simplex virus byin vivo administration of interleukin 2. J Immunol 1985; 134:926–930
Lotze MT, Frana LW, Sharrow SO, et al:In vivo administration of purified human interleukin 2:1. Half-life and immunologic effect of the Jurkat cell line-derived interleukin 2. J Immunol 1985; 134:157–166
Rouse BT, Miller LS, Turtinen L, et al: Augmentation of immunity to herpes simplex virus byin vivo administration of interleukin 2. J Immunol 1985; 134:926–930
Yamamoto S, Mizoguchi Y, Kuroki T, et al: A clinical trial of interleukin-2 treatment on HBe antigen-positive chronic hepatitis. In: Oda T, Okuda K, eds. New trends in hepatology, Medical Tosho Co, Ltd, Tokyo. 1986; 80–89
Hinuma S, Onda H, Naruo K, et al: Translation of interleukin 2m RNA from human peripheral blood leukocytes in Xenopus oocytes. Biochem Biophys Res Commun 1982; 109:363–369
Ortaldo JR, Mason AT, Gerald JP, et al: Effects of natural and recombinant IL2 on regulation of IFN-gamma production and natural killer activity: Lack of involvement of the TAC antigen for these immunoregulatory effects. J Immunol 1984;133:779–783
Kato K, Naruo K, Koyama M, et al: Purification and partial sequence analysis of human interleukin-2 derived from peripheral blood leukocytes. Biochem Biophys Res Commun 1985; 127:182–190
Perlamnn P and Holm G: Cytotoxic effects of lymphoid cellsin vitro. Adv Immunol 1969; 11:117–185
Jerne NK and Nordin AA: Plaque formation in agar by single antibody-producing cells. Science 1963; 140:405
Stötter H, Rüde E, Wagner H: T cell factor (interleukin 2) allowsin vivo induction of T helper cells against heterologous erythrocytes in athymic (nu/nu) mice. Eur J Immunol 1980; 10:719–722
Hefeneider SH, Conlon PJ, Henney CS, et al:In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells. J Immunol 1983; 130:222–227
Chang AE, Hyatt CL, Rosenberg SA: Systemic administration of recombinant human interleukin 2 in mice. J Biol Response Mod 1984; 3:561–572
Lanier LL, Benike CJ, Phillips JH, et al: Recombinant interleukin 2 enhanced, natural killer cell-mediated cytotoxicity in human lymphocyte subpopulation expressing the Leu 7 and Leu 11 antigens. J Immunol 1985; 134:794–801
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mizoguchi, Y., Shin, T., Sakagami, Y. et al. Effects of recombinant interleukin 2 on immunological effector cells of the peripheral blood in patients with HBe antigen-positive chronic hepatitis. Gastroenterol Jpn 23, 147–152 (1988). https://doi.org/10.1007/BF02799026
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02799026